Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 13, Issue 2, Pages 138-146Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-011-0161-8
Keywords
Lung; Heart; Sleep apnea; Cardiovascular; Hypoxemia; Vascular
Categories
Funding
- National Institutes of Health
- American Heart Association
- Sepracor
- Cephalon
- Philips
- Pfizer
- Merck
- SGS
- SHC
- Ethicon
- Medtronic
- Apnex
- Apnicure
- Itamar
Ask authors/readers for more resources
Obstructive sleep apnea (OSA) is a common disorder with major neurocognitive and cardiovascular sequelae. It is estimated that more than one quarter of the population is at risk for OSA, with increased prevalence noted in populations with hypertension, coronary artery disease, stroke, and atrial fibrillation. A number of epidemiologic and mechanistic studies have recently generated interest in the role of OSA in the pathophysiology of cardiovascular disease, a link that continues to require extensive investigation. This chapter reviews these epidemiologic studies, the current understanding of the mechanisms by which OSA may contribute to the progression of cardiovascular diseases, and the effects of OSA treatment on cardiovascular disease outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available